Focused On-demand Library for Mitofusin-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Transmembrane GTPase MFN2

Alternative UPACC:

O95140; A8K1B3; O95572; Q5JXC3; Q5JXC4; Q9H131; Q9NSX8


Mitofusin-2, a mitochondrial outer membrane GTPase, plays a pivotal role in mitochondrial dynamics, influencing both mitochondrial clustering and fusion. Its activity is crucial for maintaining the equilibrium between mitochondrial fusion and fission, which in turn determines mitochondrial morphology. Notably, Mitofusin-2's function extends beyond structural organization, contributing to mitochondrial metabolism, potentially impacting obesity, apoptosis, vascular smooth muscle cell proliferation, and the clearance of damaged mitochondria through mitophagy.

Therapeutic significance:

Given its involvement in Charcot-Marie-Tooth disease types 2A2A and 2A2B, and hereditary motor and sensory neuropathy with optic atrophy, Mitofusin-2 represents a significant target for therapeutic intervention. Understanding the role of Mitofusin-2 could open doors to potential therapeutic strategies, particularly in addressing the underlying genetic variants that contribute to these neuropathies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.